跳至主要内容
临床试验/EUCTR2017-000739-15-Outside-EU/EEA
EUCTR2017-000739-15-Outside-EU/EEA进行中(未招募)1 期

A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia

Eli Lilly and Company0 个研究点开始时间: 2021年12月2日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • patients must meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for Attention-Deficit/Hyperactivity Disorder (ADHD)
  • patients must achieve a score of 80 or more on the Full Scale Intelligence Quotient
  • child or adolescent patients must be 10 to 16 years old
  • must be able to communicate in English
  • must be able to swallow capsules
  • be reliable to keep appointments for clinic visits and all related tests
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 209
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • patients who weigh less than 25 Kg or greater than 70 Kg
  • patients with a history of alcohol or drug abuse on a repeated basis within the past 3 months
  • patients with documented history of autism, Asperger's syndrome or pervasive developmental disorder
  • females who are pregnant or breastfeeding
  • patients with a history of severe allergy to more than one class of medications
  • patients with documented history of bipolar I or bipolar II disorder, or psychosis

研究者

相似试验

Treatment of ADHD With Atomoxetine in Children &... | 临床试验